Publications of Udo Reichl

Hellwig, P.; Kautzner, D.; Benndorf, D.; Reichl, U.: Identification of newly synthesized proteins in microbial communities using BONCAT and click chemistry. 5^th International Metaproteomics Symposium, Avignon (France) (2023)

Hoang Son, T.; Lange, F.; Fattouh, N.; Rexer, T.; Reichl, U.: Process development for multi-gram-scale synthesis of nucleotide sugars using in-vitro multi-enzyme cascades. Eurocarb21 (The 21^st European Carbohydrate Symposium), Paris (France) (2023)

Hoang Son, T.; Wormstall, S.-T.; Rexer, T.; Reichl, U.: Development of an in-vitro multi-enzyme cascade for the synthesis of uridine diphosphate N-acetylgalactosamine using a DoE approach. GlycoBioTec 2023, Berlin, Germany (2023)

Küchler, J.; Opitz, P.; Rüdiger, D.; Kupke, S. Y.; Genzel, Y.; Benndorf, D.; Reichl, U.: Absolute quantification of influenza A virus proteins during single-round replication in different host cells. 6^th Workshop on Virus Dynamics, Nagoya (Japan) (2023)

Kupke, S. Y.; Dogra, T.; Pelz, L.; Hein, M. D.; Ndeir, N.; Rand, U.; Boehme, J.; Baelkner, M.; Kershaw, O.; Winkler, M. et al.; Cicin-Sain, L.; Bruder, D.; Pöhlmann, S.; Reichl, U.: Influenza A virus defective interfering particles as antiviral agents. 32^nd Annual Meeting of the Society for Virology (GfV), Ulm (Germany) (2023)

Pelz, L.; Dogra, T.; Boehme, J.D.; Hein, M. D.; Marichal-Gallardo, P.; Genzel, Y.; Bruder, D.; Kupke, S. Y.; Reichl, U.: Influenza A virus OP7 defective interfering particles: Cell culture-based production and antiviral efficacy in vivo. Cell Culture Engineering (CCE) XVIII , Cancun (Mexico) (2023)

Pelz, L.; Genzel, Y.; Kupke, S. Y.; Reichl, U.: In-depth characterization and cell culture-based production of influenza A virus defective interfering particles. ACTIP fellowship session, Dublin (Ireland) (2023)

Pelz, L.; Rüdiger, D.; Dogra, T.; Alnaji, F. D.; Genzel, Y.; Brooke, C. B.; Kupke, S. Y.; Reichl, U.: Semi-continuous Propagation of Influenza A Virus and Its Defective Interfering Particles: Analyzing the Dynamic Competition To Select Candidates for Antiviral Therapy. Vir-AI-DIP Workshop, Hamburg (Germany) (2023)

Rexer, T.; Hoang Son, T.; Alcalá Orozco, E. A.; Juárez-Osorio, M.; Kleeberg, S.; Reichl, U.: Activated sugar for oligosaccharides synthesis. GlycoBioTec 2023, Berlin, Germany (2023)

Rüdiger, D.; Küchler, J.; Piasecka, J.; Pontes, C.; Kupke, S. Y.; Reichl, U.: OP7, a defective interfering particle with mutations: in vitro infection experiments, intracellular model, impact of mutations and mode of antiviral action. 6^th Workshop on Virus Dynamics, Nagoya (japan) (2023)

Rüdiger, D.; Pelz, L.; Hein, M. D.; Kupke, S. Y.; Reichl, U.: Multiscale model of influenza A virus and defective interfering particle co-infection in animal cell culture. Vir-AI-DIP Workshop, Hamburg (Germany) (2023)

Wenzel, L.; Rexer, T.; Reichl, U.: Synthesis of Synthetic Lipid-Linked Oligosaccharides for In-Vitro Glycoengineering of Hemagglutinin Peptides by a Cell-Free, Multi-Enzyme Cascade. GlycoBioTec 2023, Berlin, Germany (2023)

Wenzel, L.; Ruhnau, J.; Rexer, T.; Reichl, U.: Chemoenzymatic glycosylation of polypeptides using eukaryotic oligosaccharyltransferase and synthetic lipid-linked glycans. Glyco26, Taipei (Taiwan) (2023)

Zinnecker, T. M.; Badri, N.; Araujo, D.; Hinkelmann, A.; Thiele, K.; Reichl, U.; Genzel, Y.: Novel approach towards vaccine manufacturing: from single-cell cloning to high-yielding influenza virus production. 4^th Global Bioprocessing, Bioanalytics and ATMP Manufacturing Congress, Dublin (Ireland) (2023)

Zinnecker, T. M.; Badri, N.; Araujo, D.; Hinkelmann, A.; Thiele, K.; Reichl, U.; Genzel, Y.: A quest for the best influenza producing clonal MDCK cell line: intensifying by design of experiments, ambr15 and bench-top bioreactor cultivations. World Biopharm Forum 2023 - Democratisation of biotherapies: new manufacturing modalities and intensifications, Oxford (United Kingdom) (2023)

Zuniga-Banuelos, F. J.; Hoffmann, M.; Budimir, I.; Reichl, U.; Rapp, E.: New avenues for biomarker discovery in human blood plasma via an improved in-depth analysis of the low-abundant N-glycoproteome. GlycoBioTec 2023, Berlin, Germany (2023)

Göbel, S.; Pelz, L.; Behrendt, I.; Prömmel, M.; Altomonte, J.; Anderlei, T.; Bürgin, T.; Genzel, Y.; Reichl, U.: Scale-Down of an Ortbital Shaken Bioreactor: High Cell Density Cultivation in Perfusion Mode and Virus production. Single-Use Technologies V: Building the Future, Marseille, France (2022)

Gränicher, G.; Göbel, S.; Marichal-Gallardo, P.; Jordan, I.; Sandig, V.; Genzel, Y.; Reichl, U.: Integrated cell-culture based MVA virus production process with perfusion mode for vaccines or gene therapy. Value through intensified bioprocessing II, Oxford, United Kingdom (2022)

Gränicher, G.; Göbel, S.; Marichal-Gallardo, P.; Jordan, I.; Sandig, V.; Genzel, Y.; Reichl, U.: Integrated cell-culture based MVA virus production process with perfusion mode for vaccines or gene therapy. 27th ESACT Meeting, Lisbon (Portugal) (2022)

Hein, M.; Chawla, A.; Arora , P.; Cattaneo, M.; Winkler, M.; Pöhlmann, S.; Schughart, K.; Genzel, Y.; Kupke, S. Y.; Reichl, U.: Production of influenza A virus defective interfering particles in a high cell density perfusion cultivation with continuous virus harvesting. Vaccine Technology VIII, Sitges (Spain) (2022)